Literature DB >> 19383363

'Tackling cancer in the EU: the role of innovation'.

Georgs Andrejevs, Julio E Celis, Guido Guidi, Alojz Peterle, Richard Sullivan, Roger Wilson.   

Abstract

The objective of the workshop was to examine what Cancer Innovation in Europe means and what it should be standing for in the future. The panel discussion brought together patients, researchers, politicians and industry in order to examine what cancer innovation represents to them, what the challenges are to innovation, and how innovation in this research area can be encouraged and developed in the EU.

Entities:  

Mesh:

Year:  2008        PMID: 19383363      PMCID: PMC5527872          DOI: 10.1016/j.molonc.2008.12.003

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  4 in total

1.  Returns on research and development for 1990s new drug introductions.

Authors:  Henry Grabowski; John Vernon; Joseph A DiMasi
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

2.  Turning the Stockholm Declaration into reality: Creating a world-class infrastructure for cancer research in Europe.

Authors:  Hannah Brown
Journal:  Mol Oncol       Date:  2008-11-17       Impact factor: 6.603

3.  The Stockholm declaration.

Authors:  Ulrik Ringborg
Journal:  Mol Oncol       Date:  2008-03-21       Impact factor: 6.603

4.  'Tackling cancer in the EU: the role of innovation'.

Authors:  Georgs Andrejevs; Julio E Celis; Guido Guidi; Alojz Peterle; Richard Sullivan; Roger Wilson
Journal:  Mol Oncol       Date:  2008-12-25       Impact factor: 6.603

  4 in total
  3 in total

1.  The role of funding and policies on innovation in cancer drug development.

Authors:  P Kanavos; R Sullivan; G Lewison; W Schurer; S Eckhouse; Z Vlachopioti
Journal:  Ecancermedicalscience       Date:  2010-02-03

2.  'Tackling cancer in the EU: the role of innovation'.

Authors:  Georgs Andrejevs; Julio E Celis; Guido Guidi; Alojz Peterle; Richard Sullivan; Roger Wilson
Journal:  Mol Oncol       Date:  2008-12-25       Impact factor: 6.603

Review 3.  Challenging the heterogeneity of disease presentation in malignant melanoma-impact on patient treatment.

Authors:  A Marcell Szasz; Johan Malm; Melinda Rezeli; Yutaka Sugihara; Lazaro H Betancourt; Daniel Rivas; Balázs Gyorffy; György Marko-Varga
Journal:  Cell Biol Toxicol       Date:  2018-10-24       Impact factor: 6.691

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.